Bucetin

CAS No. 1083-57-4

Bucetin ( —— )

Catalog No. M10330 CAS No. 1083-57-4

Bucetin is a pharmaceutical drug that acts as an analgesic and antipyretic.

Purity : >98%(HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 42 In Stock
200MG 61 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Bucetin
  • Note
    Research use only, not for human use.
  • Brief Description
    Bucetin is a pharmaceutical drug that acts as an analgesic and antipyretic.
  • Description
    Bucetin is a pharmaceutical drug that acts as an analgesic and antipyretic. Chemically, it is similar to phenacetin with which it shares the risk of carcinogenesis. Bucetin was withdrawn from use in 1986 due to renal toxicity
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    1083-57-4
  • Formula Weight
    223.27
  • Molecular Formula
    C12H17NO3
  • Purity
    >98%(HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CCOC1=CC=C(NC(=O)CC(C)O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Togei, K, et al. Journal of the National Y Institute, 79 (5): 1151–8.
molnova catalog
related products
  • Sodium carbonate

    Sodium Carbonate, also named as Disodium carbonate, Soda Ash, Carbonic acid disodium salt, is the disodium salt of carbonic acid with alkalinizing property.

  • 1-(2-Hydroxyethyl)im...

    Used as pharmaceutical intermediates.

  • 2,5-Dideoxyadenosine

    2',5'-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor via binding the P-site (IC50: 3 μM).2',5'-Dideoxyadenosine (20-150 mM), like adenosine, dependently and reversibly inhibits the positive inotropic and chronotropic effect of beta-adrenergic stimulation with isoproterenol (8-54 pmol) up to 70% and 50%, respectively.